BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/10/2026 9:09:43 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-04-22 10:07 |
|
Peer-Review Started |
|
2026-04-22 10:07 |
|
First Decision by Editorial Office Director |
|
2026-05-20 08:16 |
|
Return for Revision |
|
2026-05-20 08:16 |
|
Revised |
|
2026-06-10 09:56 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-07-15 02:52 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-15 03:45 |
|
Articles in Press |
|
2026-07-15 03:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-09-22 10:05 |
|
Publish the Manuscript Online |
|
2026-10-10 09:09 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Evolocumab intensive lipid-lowering therapy on prognosis of post-cerebral infarction depression
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yue Yang, Hong-Yan Song, Meng-Jun Zhang, Shu-Gen Wang and Wan-Gen Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Key Research and Development Program of Cangzhou |
23244102156 |
|
| Corresponding Author |
Yue Yang, Department of Pharmacy, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou 061000, Hebei Province, China. 825994864@qq.com |
| Key Words |
Post-cerebral infarction depression; Evolocumab; Intensive lipid-lowering therapy; Prognosis; Proprotein convertase subtilisin/kexin type 9; Neuroinflammation; Functional recovery |
| Core Tip |
This retrospective study shows that evolocumab lipid-lowering therapy greatly ameliorates the multi-dimensional prognosis in patients with post-cerebral infarction depression. The remission rates for depression nearly doubled (58.3% vs 31.9%) associated with concurrent improvements in cognition, functional independence, and rehospitalization. This parallel reduction in inflammatory markers with proprotein convertase subtilisin/kexin type 9 further supports a neuroinflammation-mediated mechanism. These results delineate evolocumab as an approach with dual therapeutic implications mitigating cardiovascular risk and neuropsychiatric sequelae in patients post-cerebral infarction. |
| Publish Date |
2026-10-10 09:09 |
| Citation |
Yang Y, Song HY, Zhang MJ, Wang SG, Liu WG. Evolocumab intensive lipid-lowering therapy on prognosis of post-cerebral infarction depression. World J Psychiatry 2026; 16(10): 121270
|
| URL |
https://www.wjgnet.com/2220-3206/full/v16/i10/121270.htm |
| DOI |
https://doi.org/10.5498/wjp.121270 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
